
Standard BioTools Inc
NASDAQ:LAB

Gross Margin
Standard BioTools Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
US |
![]() |
Standard BioTools Inc
NASDAQ:LAB
|
496.6m USD |
47%
|
|
US |
P
|
PerkinElmer Inc
LSE:0KHE
|
995.3B USD |
56%
|
|
US |
![]() |
Thermo Fisher Scientific Inc
NYSE:TMO
|
183B USD |
41%
|
|
US |
![]() |
Danaher Corp
NYSE:DHR
|
149.7B USD |
60%
|
|
KR |
![]() |
Samsung Biologics Co Ltd
KRX:207940
|
73.5T KRW |
53%
|
|
CH |
![]() |
Lonza Group AG
SIX:LONN
|
38.5B CHF |
33%
|
|
CN |
![]() |
WuXi AppTec Co Ltd
SSE:603259
|
293B CNY |
43%
|
|
US |
![]() |
Agilent Technologies Inc
NYSE:A
|
34.2B USD |
54%
|
|
US |
![]() |
IQVIA Holdings Inc
NYSE:IQV
|
32.3B USD |
34%
|
|
US |
![]() |
Mettler-Toledo International Inc
NYSE:MTD
|
27.5B USD |
60%
|
|
FR |
![]() |
Sartorius Stedim Biotech SA
PAR:DIM
|
17.1B EUR |
45%
|
Standard BioTools Inc
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.

See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Standard BioTools Inc's most recent financial statements, the company has Gross Margin of 47%.